We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with the upcoming FDA meeting in October for AZ-004 Staccato loxapine, we ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big [...]
Penny Stock Pick Feature ALXA Alexza Pharmaceuticals, Inc.
We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with… [more]
ACAD featured Phase 3 play
We have added ACADIA Pharmaceuticals Inc. (ACAD): Nasdaq to our featured and our watch list today and… [more]
Arena Pharmaceuticals, Inc. ARNA : Nasdaq
ARNA could start to become quite interesting play on the run up to the NDA, The FDA has notified the… [more]
RPRX featured FDA play
This could be a little gem short term and seems to be hidden FDA play, Repros Requests a lift of the… [more]
Featured Penny Picks
ACAD featured Phase 3 play
We have added ACADIA Pharmaceuticals Inc. (ACAD): Nasdaq to our featured and our watch list today and ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big moves. ACADIA Pharmaceuticals Inc. (ACAD) : Nasdaq ) Currently trading on [...]
Arena Pharmaceuticals, Inc. ARNA : Nasdaq
ARNA could start to become quite interesting play on the run up to the NDA, The FDA has notified the company of the tentative scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application. The shares are trading up pre market on [...]
Top News
Inhibitex Successfully Completes Phase 1a Trial of INX-189
Inhibitex, Inc. (Nasdaq:INHX – News)announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 [...]
Alexza’s Staccato® Nicotine Licensed to Cypress Bioscience
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq:CYPB – News). The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by [...]
FDA panel rejects Jazz drug
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) U.S. advisory panel on Friday rejected a Jazz Pharmaceuticals Inc (JAZZ.O) Nasdaqmedicine to treat the pain disorder fibromyalgia amid concerns the product could be misused as a “date-rape” drug. A Food and Drug Administration advisory committee voted 20-2 against recommending approval of sodium oxybate or JZP-6. The medicine contains a [...]
RPRX has received positive written feedback from the FDA
Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has received positive written feedback from the FDA (the “Agency”) regarding the Company’s drug candidate Androxal®. The Agency concurred with Repros’ indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility. In the written advice letter the [...]
Press Releases
Inhibitex Successfully Completes Phase 1a Trial of INX-189
Inhibitex, Inc. (Nasdaq:INHX – News)announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 [...]
Alexza’s Staccato® Nicotine Licensed to Cypress Bioscience
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq:CYPB – News). The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by [...]
FDA panel rejects Jazz drug
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) U.S. advisory panel on Friday rejected a Jazz Pharmaceuticals Inc (JAZZ.O) Nasdaqmedicine to treat the pain disorder fibromyalgia amid concerns the product could be misused as a “date-rape” drug. A Food and Drug Administration advisory committee voted 20-2 against recommending approval of sodium oxybate or JZP-6. The medicine contains a [...]
Stock Chit Chat
Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference. The Alexza presentation will be on Friday, August 13, 2010 at 10:40 am ET. The presentation will be webcast from the Southampton [...]
RPRX Back in Play
Penny stock picks gave the heads up on RPRX in June on Proellex lift, and now there could be a chance to make more money on this penny stock play with Androxal. And we have are adding this to our radar on FDA news for Androxal. RPRX : (Nasdaq) Are awaiting response from the FDA [...]
ARNA Arena Pharma stock offering
Arena Pharmaceuticals Inc. said Friday it expects to receive about $60 million before expenses from a direct public offering of stock to entities tied to the health investment firm Deerfield Management. Arena, which is based in San Diego, said it will sell a total of about 8.9 million shares for $6.70 per share. The offering [...]